Načítá se...
Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain – a cost-effectiveness comparison
BACKGROUND: In schizophrenia, medication adherence is critical to achieve better patient outcomes and to avoid relapses, which are responsible for a significant proportion of total healthcare costs for this chronic illness. The aim of this study was to assess the cost-effectiveness of olanzapine lon...
Uloženo v:
| Vydáno v: | BMC Psychiatry |
|---|---|
| Hlavní autoři: | , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2014
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4268824/ https://ncbi.nlm.nih.gov/pubmed/25438678 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12888-014-0298-4 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|